北大医药(000788) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was ¥526,202,037.02, a decrease of 7.95% compared to the same period last year[2] - Net profit attributable to shareholders was ¥43,539,592.87, an increase of 202.39% year-over-year[2] - Basic earnings per share for Q3 2024 was ¥0.0731, reflecting a growth of 202.07% compared to the previous year[2] - Total operating revenue for the third quarter was ¥1,534,330,245.12, a decrease of 7.3% compared to ¥1,655,471,575.84 in the same period last year[16] - The net profit for the third quarter of 2024 was CNY 130,313,731.08, a significant increase from CNY 46,109,690.65 in the same period last year, representing an increase of approximately 182.5%[17] - Operating profit for the third quarter reached CNY 163,931,888.07, compared to CNY 65,000,552.83 in the previous year, marking an increase of about 152.3%[17] - Earnings per share for the third quarter were CNY 0.2187, up from CNY 0.0774 in the same quarter last year, representing an increase of approximately 182.5%[17] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥2,327,826,491.93, down 4.53% from the end of the previous year[2] - Total liabilities decreased to ¥791,597,294.77 from ¥1,016,874,986.96, indicating improved financial health[15] - Cash and cash equivalents in current assets were reported at ¥1,966,287,622.62, down from ¥2,052,936,020.77, reflecting liquidity challenges[15] - Cash and cash equivalents at the end of the period totaled CNY 330,178,314.04, down from CNY 513,512,422.27 at the beginning of the period, reflecting a decrease of approximately 35.6%[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥63,852,931.12, a significant increase of 464.24% year-over-year[5] - Cash flow from operating activities generated a net amount of CNY 63,852,931.12, a turnaround from a negative cash flow of CNY -17,530,455.81 in the same quarter last year[18] - The company experienced a net cash outflow from financing activities of CNY -61,945,566.84, compared to CNY -199,030,153.78 in the previous year, indicating an improvement in cash flow management[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,939, with the largest shareholder holding 22.22% of the shares[6] - The top shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., holds 132,455,475 shares, representing 100% of its holdings[7] - Beijing Medical Management Co., Ltd. holds 70,328,949 shares, also representing 100% of its holdings[7] - As of the end of the reporting period, the total shares held by the top 10 shareholders amount to 132,455,475 shares, with 60,107,360 shares involved in margin trading[7] - A total of 27,565,085 shares held by Beijing Medical Management Co., Ltd. have been pledged[9] Expenses and Cost Management - The company reported a decrease in sales expenses by 55.00% to ¥168,872,186.41 for the year-to-date[5] - Total operating costs decreased to ¥1,371,419,826.74, down 13.8% from ¥1,591,060,483.98 year-over-year[16] - Gross profit margin improved to approximately 10.6% from the previous year's margin, reflecting better cost management[16] - The company reported a decrease in financial expenses, with interest expenses at CNY 2,421,511.97, down from CNY 5,481,854.12 in the previous year, a reduction of about 55.8%[17] Research and Development - Research and development expenses increased to ¥19,360,593.13, up from ¥14,096,917.97, highlighting a commitment to innovation[15] - Research and development expenses amounted to CNY 13,294,511.08, compared to CNY 13,816,597.37 in the same quarter last year, indicating a decrease of approximately 3.8%[17] Corporate Actions - The company’s wholly-owned subsidiary, Shanghai Founder TuoKang Trading Co., Ltd., has completed its deregistration[8] - The company received approval from the National Medical Products Administration for the registration of its product, Levocetirizine Hydrochloride Oral Solution, confirming compliance with registration requirements[11] - The company announced a cash dividend distribution plan for the 2023 fiscal year, proposing a distribution of RMB 0.26 per 10 shares, totaling approximately RMB 15.5 million based on a total share capital of 595,987,425 shares[11] - The company plans to distribute a cash dividend of RMB 0.50 per 10 shares for the first half of 2024, amounting to a total of approximately RMB 29.8 million, pending shareholder approval[11] - The company held its annual general meeting on June 27, 2024, where it elected the 11th board of directors and supervisory board members, ensuring governance continuity[10] - The company signed a fixed asset lease agreement with Chongqing Southwest Synthetic Pharmaceutical Co., Ltd., for a three-year term starting January 1, 2024, indicating strategic asset management[10] Other Financial Metrics - The company’s weighted average return on equity was 3.05% for Q3 2024, an increase of 2.01% compared to the previous year[2] - The total equity attributable to shareholders increased by 8.08% to ¥1,536,926,837.92 compared to the end of the previous year[2] - Non-recurring gains and losses totaled ¥481,704.02 for Q3 2024, with government subsidies contributing ¥524,003.91[3] - Long-term equity investments increased to ¥3,257,509.74, indicating a focus on strategic investments[15] - Non-current assets totaled ¥361,538,869.31, down from ¥385,350,105.31, showing a reduction in asset base[15] - Accounts receivable decreased from RMB 1.25 billion to RMB 1.20 billion, a reduction of about 3.8%[13] - Inventory increased from RMB 184.18 million to RMB 208.54 million, representing a growth of approximately 13.2%[13] - The company has completed the payment of overdue taxes and penalties totaling RMB 19.45 million, covering the period from 2019 to May 31, 2023[10]